SGLT2 Inhibitors-A Medical Revelation: Molecular Signaling of Canagliflozin Underlying Hypertension and Vascular Remodeling

J Am Heart Assoc. 2022 Aug 2;11(15):e026774. doi: 10.1161/JAHA.122.026774. Epub 2022 Jul 29.
No abstract available

Keywords: Editorials; heart failure; high blood pressure; hypertension; mechanisms; myocardial infarction.

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Canagliflozin / therapeutic use
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypertension* / drug therapy
  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
  • Vascular Remodeling

Substances

  • Hypoglycemic Agents
  • Sodium-Glucose Transporter 2
  • Sodium-Glucose Transporter 2 Inhibitors
  • Canagliflozin